Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Double chin

- PMLiVE

Bayer’s Eylea data not suitable, says IQWiG

German HTA body unhappy with Lucentis comparison data and turns down Bayer-Regeneron wet AMD drug

- PMLiVE

Mixed reaction to Novo Nordisk obesity trial

Analyst says Victoza only has a modest ability to reduce weight in people with diabetes

- PMLiVE

Bayer sues Glenmark over its skin disorder generic

India-based firm files for US approval of its version of Finacea

- PMLiVE

Merck & Co’s sugammadex delayed in US

FDA says it needs more time to review application

- PMLiVE

FDA investigates pancreas risk of diabetes drugs

Products from Merck & Co, BMS, AZ, Novo Nordisk, Boehringer, Amylin and Takeda all involved

Novartis building

FDA deems Novartis lung cancer drug a “breakthrough therapy”

LDK378 will have accelerated passage through development

- PMLiVE

FDA explains draft Alzheimer’s guidance in NEJM editorial

Intends to relax requirements in patient function and cognition

FDA smartphone regulation could stifle innovation

US House Republicans issue warning on guidance and call for more information

- PMLiVE

FDA knocks back Xarelto once again in ACS

Major setback for Bayer and Johnson & Johnson's oral anticoagulant

- PMLiVE

Bayer fails to overturn Nexavar compulsory licence in India

Natco Pharma allowed to sell cut-price version of cancer drug

- PMLiVE

Bayer pins hopes on five potential blockbusters

Riociguat, alpharadin, Stivarga, Eylea, and Xarelto expected to reach sales of €5.5bn by 2015

- PMLiVE

Second approval in US for Bayer-Onyx’ Stivarga

FDA clears drug to treat patients with gastrointestinal stromal tumours

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links